European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism
- 8 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 31 (8), 1461-1470
- https://doi.org/10.1007/s00198-020-05362-8
Abstract
Summary We have calculated the biological variation (BV) of different bone metabolism biomarkers on a large, well-described cohort of subjects. BV is important to calculate reference change value (or least significant change) which allows evaluating if the difference observed between two consecutive measurements in a patient is biologically significant or not. Introduction Within-subject (CVI) and between-subject (CVG) biological variation (BV) estimates are essential in determining both analytical performance specifications (APS) and reference change values (RCV). Previously published estimates of BV for bone metabolism biomarkers are generally not compliant with the most up-to-date quality criteria for BV studies. We calculated the BV and RCV for different bone metabolism markers, namely β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin (OC), intact fibroblast growth factor 23 (iFGF-23), and uncarboxylated-unphosphorylated Matrix-Gla Protein (uCuP-MGP) using samples from the European Biological Variation Study (EuBIVAS). Methods In the EuBIVAS, 91 subjects were recruited from six European laboratories. Fasting blood samples were obtained weekly for ten consecutive weeks. The samples were run in duplicate on IDS iSYS or DiaSorin Liaison instruments. The results were subjected to outlier and variance homogeneity analysis before CV-ANOVA was used to obtain the BV estimates. Results We found no effect of gender upon the CVI estimates. The following CVI estimates with 95% confidence intervals (95% CI) were obtained: β-CTX 15.1% (14.4–16.0%), PINP 8.8% (8.4–9.3%), OC 8.9% (8.5–9.4%), iFGF23 13.9% (13.2–14.7%), and uCuP-MGP 6.9% (6.1–7.3%). Conclusions The EuBIVAS has provided updated BV estimates for bone markers, including iFGF23, which have not been previously published, facilitating the improved follow-up of patients being treated for metabolic bone disease.Keywords
This publication has 52 references indexed in Scilit:
- IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and childrencclm, 2013
- A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapyBone, 2009
- Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS StudyJournal of Bone and Mineral Research, 2009
- The Circulating Inactive Form of Matrix Gla Protein (ucMGP) as a Biomarker for Cardiovascular CalcificationJournal of Vascular Research, 2008
- The Intensity Level of Physical Exercise and the Bone Metabolism ResponseInternational Journal of Sports Medicine, 2005
- Changes in Bone Turnover Induced by Aerobic and Anaerobic Exercise in Young MalesJournal of Bone and Mineral Research, 1998
- Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological VariabilityJournal of Bone and Mineral Research, 1998
- Biological variation in bone-derived biochemical markers in serumScandinavian Journal of Clinical and Laboratory Investigation, 1995
- Biological variation of biochemical bone markersScandinavian Journal of Clinical and Laboratory Investigation, 1994
- THE DISTRIBUTION OF THE LARGEST OF A SET OF ESTIMATED VARIANCES AS A FRACTION OF THEIR TOTALAnnals of Eugenics, 1941